Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | FABP6 | P51161 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820441 | 0.88 | TP53 (0.42) | TP53EPHX2KDM1AEPHX1FABP6 | |
| SCHEMBL21556645 | 0.88 | TP53 (0.42) | TP53EPHX2KDM1AEPHX1FABP6 | |
| SCHEMBL5344959 | 0.80 | TP53 (0.50) | TP53EPHX2KDM1AEPHX1FABP6 | |
| SCHEMBL19091357 | 0.80 | CA1 (0.42) | TSHRL3MBTL1 | |
| SCHEMBL29259766 | 0.78 | TP53 (0.48) | TP53EPHX2KDM1AEPHX1FABP6 | |
| SCHEMBL4919816 | 0.75 | EPHX2 (0.65) | TP53EPHX2EPHX1LMNATSHR | |
| SCHEMBL774350 | 0.75 | ADH1B (0.50) | TP53EPHX2KDM1AEPHX1FABP6 | |
| SCHEMBL12448115 | 0.75 | LMNA (0.47) | TP53EPHX2KDM1AEPHX1FABP6 | |
| SCHEMBL12404039 | 0.75 | TP53 (0.46) | TP53EPHX2KDM1AEPHX1FABP6 | |
| SCHEMBL774349 | 0.75 | TP53 (0.46) | TP53EPHX2KDM1AEPHX1FABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848363-B1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC (CN) | 2023-07-19 | — | — | EP | disclosed |
| EP-3848363-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | Medshine Discovery Inc. (CN) | 2021-07-14 | — | — | EP | disclosed |
| US-10246478-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2019-04-02 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| WO-2012126084-A1 | HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE IΝ THE TREATMENT AND PREVENTION OF FUNGAL INFECTIONS | PHARMASCIENCE INC. (CA) | 2012-09-27 | — | — | WO | disclosed |
| WO-2011035417-A1 | HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE FN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | AEGERA THERAPEUTICS INC. (CA) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | TP53 3681/4885EPHX2 3988/4885KDM1A 3551/4885 |
| US-10246478-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | TP53 3681/4885EPHX2 3988/4885KDM1A 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.